Steven Cohen's CYTK Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 626,102 shares of Cytokinetics, Incorporated (CYTK) worth $41.27 M, representing 0.05% of the portfolio. First purchased in 2019-Q2, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in CYTK, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2019, adding 2.59 M shares. Largest reduction occurred in Q1 2020, reducing 2.24 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Cytokinetics Incorporated (CYTK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytokinetics Incorporated (CYTK) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +626,102 | New Buy | 626,102 | $65.91 |
| Q4 2025 | -471,482 | Sold Out | 0 | $0.00 |
| Q3 2025 | +471,482 | New Buy | 471,482 | $54.96 |
| Q2 2025 | -1.72 M | Sold Out | 0 | $0.00 |
| Q1 2025 | +1.55 M | Add 914.04% | 1.72 M | $40.19 |
| Q4 2024 | -294,097 | Reduce 63.38% | 169,913 | $47.04 |
| Q3 2024 | +89,162 | Add 23.79% | 464,010 | $52.80 |
| Q2 2024 | +10,139 | Add 2.78% | 374,848 | $54.18 |
| Q1 2024 | +207,609 | Add 132.15% | 364,709 | $70.11 |
| Q4 2023 | +157,100 | New Buy | 157,100 | $83.49 |
| Q3 2023 | -160,400 | Sold Out | 0 | $0.00 |
| Q2 2023 | +160,400 | New Buy | 160,400 | $32.62 |
| Q1 2023 | -271,500 | Sold Out | 0 | $0.00 |
| Q4 2022 | +239,500 | Add 748.44% | 271,500 | $45.82 |
| Q3 2022 | +12,367 | Add 62.99% | 32,000 | $48.44 |
| Q2 2022 | -1.6 M | Reduce 98.79% | 19,633 | $39.27 |
| Q1 2022 | +737,146 | Add 83.25% | 1.62 M | $36.81 |
| Q4 2021 | -123,846 | Reduce 12.27% | 885,454 | $45.58 |
| Q3 2021 | +681,800 | Add 208.18% | 1.01 M | $35.74 |
| Q2 2021 | -47,100 | Reduce 12.57% | 327,500 | $19.79 |
| Q1 2021 | -791,694 | Reduce 67.88% | 374,600 | $23.26 |
| Q4 2020 | -440,056 | Reduce 27.39% | 1.17 M | $20.78 |
| Q3 2020 | +1.28 M | Add 389.33% | 1.61 M | $21.65 |
| Q2 2020 | -462,923 | Reduce 58.51% | 328,277 | $23.57 |
| Q1 2020 | -2.24 M | Reduce 73.88% | 791,200 | $11.79 |
| Q4 2019 | +2.59 M | Add 597.71% | 3.03 M | $10.61 |
| Q3 2019 | -172,900 | Reduce 28.48% | 434,100 | $11.38 |
| Q2 2019 | +607,000 | New Buy | 607,000 | $11.25 |
Steven Cohen's Cytokinetics Incorporated Investment FAQs
Steven Cohen first purchased Cytokinetics, Incorporated (CYTK) in Q2 2019, acquiring 607,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Cytokinetics, Incorporated (CYTK) for 28 quarters since Q2 2019.
Steven Cohen's largest addition to Cytokinetics, Incorporated (CYTK) was in Q4 2019, adding 3,028,751 shares worth $32.14 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 626,102 shares of Cytokinetics, Incorporated (CYTK), valued at approximately $41.27 M.
As of the Q1 2026 filing, Cytokinetics, Incorporated (CYTK) represents approximately 0.05% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Cytokinetics, Incorporated (CYTK) was 3,028,751 shares, as reported at the end of Q4 2019.